10 Responses

Page 1 of 1
  1. Devon Walters
    Devon Walters at |

    Well written!! I’d like to also add, that if you read the details of the lawsuit from 2011, it appears that King – (Phizer?/Mylan) kept Sanofi off of the market for over 14 months. For them to do this just to keep marketshare for as long as possible is sickening when this could have been an option for patients sooner. This epitomizes what is wrong with big Pharma. As to the CEO of Mylan’s comments – if you read into that, she is lashing out and attacking this new innovation, ie – Auvi-q, because she is scared. Also, the Auvi-q is nothing like the Twinject or the Adrenaclick, which were other “Pens” with very little differentiation from the Epi-Pen. She stated that the Epi-Pen is “tried and true” – give me a break. Do you know how many people inject their thumbs with the Epi-Pen each year because they think the orange needle cover is the activation button when they are in the heat of a reaction? It’s a whole lot more than you would think. Check out this article out that I found – http://www.sciencedirect.com/science/article/pii/S0091674909016339
    As for me, I am glad to see a new option available that finally meets the needs of us patients.

  2. Cheryl
    Cheryl at |

    Competition. Something new and hopefully improved has hit the market. This will serve the FA community well. The size is a big complaint by millions. After 20-25 years it’s about time the product has been improved. Look forward to the next generation of injectors. Hopefully this friendly competition will excite the research needed to provide better options. We are definitely asking our physician for an Rx for auvi q.

  3. Selena Bluntzer
    Selena Bluntzer at |

    Great post – took the thoughts right out of my head, and then some!

  4. Jennifer B
    Jennifer B at |

    Thanks so much for this fantastic blog post. Things are definitely building. Both Mylan and Sanofi invited a bunch of food allergy bloggers to “blogger summits”, which sounded pretty appealing, I must admit. I was unable to attend either due to my own work. I’m also seeing a dramatic uptick in the press release emails from both companies. I am very grateful epinephrine exists and that we can get an injector with a prescription, but I am observing the competition and related marketing campaigns (and awareness campaigns) with much interest.

  5. Jennifer Ng
    Jennifer Ng at |

    Competition will drive innovation for sure on all sides and hopefully the general public will benefit. This is a very interesting product but personally I will wait a bit longer before I make any changes.

    For instance, I would monitor the next 6 months after the launch, for any reported incidents/complaints (details would be on the FDA.gov website under the medical adverse events section). I love new technology but in this case I do not want to be an early adopter because I am just not willing to take the risk of this new device malfunctioning when my son might need it the most.

    BTW Mylan has the right to challenge the “two-third” claims made by Sanofi (which is also on their website) as the FDA has strict regulations on how to present and use superiority language, esp. when discussing a competitor in advertising. However the tone of the CEO response is another matter … There is a lot of $$$ and market share at stake here and she knows it!

  6. Shelly
    Shelly at |

    I am glad that there is some competition in the market. It seems that so many people are anxious to grab up this new device. I am glad that our Epis don’t expire for awhile. I, like Jennifer, would like to sit back and observe before switching something so important for my child. I know it has been tested and is ok with the FDA, but so have some other drugs that haven’t had a happy ending. I really hope the Auvi-Q works great and I probably will get it when I’m sure it is safe. In the meantime, I’ll just take up the extra space in my purse with my 2 Epis.

  7. Yael
    Yael at |

    Do you know that Epipens used to be $30 each –thank you Dey/Mylan. If they truly want to own the market how about generic? They have been around for over 20 years –what the heck? Every Sept. i need to replace over $1000 worth of epi-pens for 3 fam members. the shelf life is only a year. $275 per double pack last month out of pocket. and we need more

  8. Tracy
    Tracy at |

    I truly feel that, as with every new product, there is always a conflict of interest that arises with a similar product and I don’t feel this is a unique case. I’m sure both companies are aiming for better publicity and better sales but what company would not want that? If anything, I lean on the positive side of things and I believe that consumers will choose the product that they feel is the best fit for them which (sometimes) doesn’t even depend on what type of additional comments are made. If this causes Mylan to step up and push back harded for the good of the people, then it’s a good thing. If it causes Sanofi to push just as hard, so be it. Either way, there is a choice for anyone who needs a choice and that’s not such a bad thing.

  9. Michele
    Michele at |

    I am a mother of a child with VERY severe food allergies. There are times when we walk out of the house without his epi-pens. They are not convenient to carry in any way. I am very petite so they don’t fit in my pockets! The design is ridiculous, I would LOVE to have the Auvi Q here in the USA!!!

Comments are closed.